Behavior Genetics

, Volume 24, Issue 3, pp 285–297

Evidence for a multigenic system controlling methyl-β-carboline-3-carboxylate (β-CCM)-induced seizures

Authors

  • Benoît Martin
    • Génétique, Neurogénétique et Comportement, URA 1294-CNRSUFR Biomédicale Paris V
  • Catherine Marchaland
    • Génétique, Neurogénétique et Comportement, URA 1294-CNRSUFR Biomédicale Paris V
  • Georges Chapouthier
    • Génétique, Neurogénétique et Comportement, URA 1294-CNRSUFR Biomédicale Paris V
  • Roland Motta
    • Laboratoire de Recherche Génétique sur les Modèles Animaux (LRGMA) (CSAL)-CNRS
Article

DOI: 10.1007/BF01067195

Cite this article as:
Martin, B., Marchaland, C., Chapouthier, G. et al. Behav Genet (1994) 24: 285. doi:10.1007/BF01067195

Abstract

β-CCM is a β-carboline known to have properties opposite to those of benzodiazepines. Our approach was to analyze, in mice, the genetic mechanisms involved in β-CCM-induced myoclonic seizures using recombinant congenic strains and F1 hybrids issued from these strains. Our aim was to define the extent of the multigenic character of β-CCM-induced myoclonic seizures, while also evaluating the distribution of the strength of the genes implicated in this trait. The results show that the control of reactivity to β-CCM is multigenic with notable epistatic involvement.

Key Words

Recombinant congenic strainsrecombinant inbred strainsβ-carbolinesmethyl-β-carboline-3-carboxylateinverse agonistγ-aminobutyric acidmice

Copyright information

© Plenum Publishing Corporation 1994